Aptose Biosciences Inc. (“Aptose” or the “Company”) is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company’s executive offices are located in San Diego, California and its head office is located in Toronto, Canada.

 

Aptose has clinical-stage programs and a program that is discovery-stage and partnered with another company. (“CG-), Aptose’s pan-FMS-like tyrosine kinase / pan-Bruton’s tyrosine kinase inhibitor, was recently approved by the U.S. Food and Drug Administration (FDA) for a phase safety trial for the treatment of patients with relapsed / refractory Acute Myeloid Leukemia (R/R AML) and patients having certain B-cell malignancies. APTO- Aptose’s program, is a small molecule MYC inhibitor and is currently enrolling patients in a Phase clinical trial for the treatment of patients with R/R blood cancers, including AML and high-risk Myelodysplastic Syndrome.